HC Wainwright Analysts Reduce Earnings Estimates for VNDA

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Stock analysts at HC Wainwright dropped their Q1 2025 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.52) per share for the quarter, down from their prior estimate of ($0.13). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals' Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at $0.22 EPS.

Separately, StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating on the stock.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA traded down $0.06 during trading on Thursday, reaching $4.43. 569,122 shares of the stock traded hands, compared to its average volume of 634,239. The stock has a 50-day moving average of $4.60 and a two-hundred day moving average of $4.82. Vanda Pharmaceuticals has a 52-week low of $3.71 and a 52-week high of $6.75. The stock has a market cap of $258.36 million, a P/E ratio of -13.84 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. The business had revenue of $53.19 million for the quarter, compared to analysts' expectations of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $240,000. Squarepoint Ops LLC raised its position in shares of Vanda Pharmaceuticals by 186.4% during the 4th quarter. Squarepoint Ops LLC now owns 71,131 shares of the biopharmaceutical company's stock valued at $341,000 after purchasing an additional 46,293 shares during the period. Two Sigma Advisers LP raised its position in shares of Vanda Pharmaceuticals by 11.2% during the 4th quarter. Two Sigma Advisers LP now owns 156,300 shares of the biopharmaceutical company's stock valued at $749,000 after purchasing an additional 15,700 shares during the period. Two Sigma Investments LP raised its position in shares of Vanda Pharmaceuticals by 94.7% during the 4th quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company's stock valued at $955,000 after purchasing an additional 97,017 shares during the period. Finally, Stonepine Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $120,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.